中国麻风皮肤病杂志 ›› 2025, Vol. 41 ›› Issue (10): 756-759.doi: 10.12144/zgmfskin202510756

• 综述 • 上一篇    下一篇

生物制剂及小分子药物治疗HIV感染合并银屑病研究进展

邹燕菲,邓雅轩,吴剑波,刘琴   

  1. 武汉大学中南医院皮肤科,湖北武汉,430071
  • 出版日期:2025-10-15 发布日期:2025-09-29

Advances in biological agents and small molecule drugs for the treatment of HIV-positive patients with psoriasis

ZOU Yanfei, DENG Yaxuan, WU Jianbo, LIU Qin   

  1. Department of Dermatology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China
  • Online:2025-10-15 Published:2025-09-29

摘要: 银屑病在HIV感染者中的发病率显著高于普通人群,临床表现更严重,治疗更困难,且更易复发。近年来,生物制剂和小分子药物在中重度银屑病的治疗中取得了突破性进展,但HIV感染者通常被排除在临床试验之外。个案报道和回顾性研究显示,HIV阳性银屑病患者接受生物制剂或小分子药物治疗后皮损改善,且未观察到HIV疾病进展或严重感染风险增加。本文就生物制剂及小分子药物治疗HIV合并银屑病的进展进行综述。

关键词: 银屑病, 人类免疫缺陷病毒, 生物制剂, 小分子药物

Abstract: The incidence of psoriasis in HIV-infected individuals is significantly higher than in the general population, with more severe clinical manifestations, greater therapeutic challenges, and a higher tendency to relapse. In recent years, biological agents and small-molecule drugs have achieved breakthrough progress in the treatment of moderate-to-severe psoriasis, however, HIV-infected individuals are usually excluded from clinical trials. Case reports and retrospective studies have shown that lesions in HIV-positive psoriasis patients respond effectively to treatment with biological agents or small-molecule drugs, with no observed progression of HIV disease or increased risk of severe infections. The advances in the treatment of HIV-associated psoriasis using biological agents and small-molecule drugs are reviewed.

Key words: psoriasis, human immunodeficiency virus, biological agents, small molecule drug